Cargando…

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer

BACKGROUND: Breast cancer is a global problem, and a large number of new cases are diagnosed every year. Capecitabine is effective in patients with metastatic breast cancer (MBC). Hand-foot syndrome (HFS) is a common adverse effect of capecitabine. In this study, we investigated the association betw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Shaoyan, Yue, Jian, Guan, Xiuwen, Yuan, Peng, Wang, Jiayu, Luo, Yang, Fan, Ying, Cai, Ruigang, Li, Qiao, Chen, Shanshan, Zhang, Pin, Li, Qing, Ma, Fei, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787984/ https://www.ncbi.nlm.nih.gov/pubmed/31601265 http://dx.doi.org/10.1186/s40880-019-0399-z

Ejemplares similares

Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer
por: Dong, Si-Qi, et al.
Publicado: (2021)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
por: Guan, Xiuwen, et al.
Publicado: (2023)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population
por: Lin, Shaoyan, et al.
Publicado: (2021)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine
por: Vitello, Stefano, et al.
Publicado: (2020)

DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients
por: Amirfallah, Arsalan, et al.
Publicado: (2018)

Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China
por: Li, Yiqun, et al.
Publicado: (2021)

Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
por: Li, Yiqun, et al.
Publicado: (2020)

Genetic Polymorphisms of TYMS, MTHFR, ATIC, MTR, and MTRR Are Related to the Outcome of Methotrexate Therapy for Rheumatoid Arthritis in a Chinese Population
por: Lv, Shuang, et al.
Publicado: (2018)

HAND-FOOT SYNDROME DUE TO CAPECITABINE
por: Surjushe, Amar, et al.
Publicado: (2009)

HAND-FOOT SYNDROME DUE TO CAPECITABINE
por: Surjushe, Amar, et al.
Publicado: (2008)

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China
por: Lin, Shaoyan, et al.
Publicado: (2020)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
por: Li, Yiqun, et al.
Publicado: (2022)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer
por: Wang, Jiayu, et al.
Publicado: (2015)

Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population
por: Mo, Hongnan, et al.
Publicado: (2022)

Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy
por: Li, Meiying, et al.
Publicado: (2018)

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial
por: He, Maiyue, et al.
Publicado: (2023)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population
por: Lin, Shaoyan, et al.
Publicado: (2021)

Association Between MTHFR Polymorphisms and the Risk of Essential Hypertension: An Updated Meta-analysis
por: Meng, Hao, et al.
Publicado: (2021)

Scleroderma in a Patient on Capecitabine: Is this a Variant of Hand-Foot Syndrome?
por: Saif, Muhammad W, et al.
Publicado: (2016)

Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity?
por: Caprez, Jennifer, et al.
Publicado: (2018)

Timing of paclitaxel treatment in pre‐operative or post‐operative does not affect survival in breast cancer patients
por: Wang, Jiayu, et al.
Publicado: (2017)

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
por: Chai, Yue, et al.
Publicado: (2023)

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2017)

Generalised Lichenoid Drug Eruption Accompanied by Hand-foot Syndrome Due to Capecitabine
por: Tamer, Funda, et al.
Publicado: (2018)

Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient
por: Whorton, Allison E, et al.
Publicado: (2022)

Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients
por: Zhang, Pin, et al.
Publicado: (2016)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts
por: Wang, Jingjing, et al.
Publicado: (2017)

Association Between Genetic Polymorphisms In TYMS And Glioma Risk In Chinese Patients: A Case-Control Study
por: Yao, Li, et al.
Publicado: (2019)

Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer
por: Junior, José da Silva Nogueira, et al.
Publicado: (2012)

Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation
por: de Queiroz, Marina Vieira Rodrigues, et al.
Publicado: (2022)

Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitor
por: Wang, Jiayu, et al.
Publicado: (2018)

Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy
por: Qian, Xiaoyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g8kj74au6vco6ghamb988eid29